Compare Annaly Capital Management, Inc. (NLY) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Annaly Capital Management, Inc. vs Revvity Inc — how do they compare? Annaly Capital Management, Inc. trades at $22.79 (market cap $17.04B), while Revvity Inc trades at $124.14 (market cap $13.82B). The key difference: Annaly Capital Management, Inc. is the larger of the two by market cap, and Annaly Capital Management, Inc. pays the higher dividend (13.27%). Which is the better fit depends on your goals.
| NLY | RVTY | |
|---|---|---|
Market Cap | $17.04B | $13.82B |
Sector | Financials | Technology |
52-Week High | $24.40 | $130.94 |
52-Week Low | $20.21 | $82.26 |
Dividend Yield | 13.27% | 0.23% |
Enterprise Value | — | $16.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Annaly Capital Management (NLY) trades at $22.72, down 0.39% for the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.79 exceeding the $0.751 estimate. Fundamentals show a high net income margin of 92.77% and a return on equity of 20.66%, though cash flow from operations declined to $692.91 million in 2025. Recent news includes a declared $0.75 dividend and a preferred stock redemption.
The outlook for NLY is supported by analyst consensus with a $24.33 price target and a majority buy rating, indicating potential upside. However, risks include significant investing cash outflows, high leverage with debt-to-asset ratio rising to 23.55 in 2025, and sensitivity to interest rate changes. The stock offers a high dividend yield but faces headwinds from mortgage rate volatility and tax inefficiencies for investors in taxable accounts.
RVTY trades at $127.08, down 2.41% over 24 hours, with a bullish technical signal driven by moving averages and strong support at $126. The company reported Q2 2026 EPS of $1.41, beating estimates, and raised its full-year outlook, supported by diagnostics growth and improved cash flow. Recent news includes the acquisition of Human Cell Design and product launches, indicating strategic expansion.
Outlook remains positive with a consensus price target of $136.20, offering ~7% upside, but high P/E of 59.54 poses valuation risk. Key opportunities include earnings momentum and innovation; risks involve premium valuation and competitive pressures in the healthcare sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
